Michael Cronquist Christensen (Cronquist Christensen M)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 26

Top Topics

Systemic Lupus Erythematosus

Clinical Practice

Top Venues

Journal of psychopharmacology (Oxford, England)

Neuropsychiatric disease and treatment

Annals of general psychiatry

This page only lists publications with an associated author ORCID identifier.

Publications

Marco Di Nicola, Michael Adair, A Rieckmann, Michael Cronquist Christensen
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study. Journal of psychopharmacology (Oxford, England) 38 (7) (2024)
Gang Wang, Tian-Mei Si, Andreas Rieckmann, Jingdong Ma, Michael Cronquist Christensen
Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study. Neuropsychiatric disease and treatment 20 (2024)
Marco Di Nicola, Michael Adair, A Rieckmann, Michael Cronquist Christensen
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study. Journal of psychopharmacology (Oxford, England) 38 (7) (2024)
Michael Cronquist Christensen, Francesca Canellas, Henrik Loft, Ángel L Montejo
Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study. Neuropsychiatric disease and treatment 20 (2024)
Marco Di Nicola, Michael Adair, A Rieckmann, Michael Cronquist Christensen
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study. Journal of psychopharmacology (Oxford, England) 38 (7) (2024)
Michael Cronquist Christensen, Francesca Canellas, Henrik Loft, Ángel L Montejo
Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study. Neuropsychiatric disease and treatment 20 (2024)
Gang Wang, Tian-Mei Si, Andreas Rieckmann, Jingdong Ma, Michael Cronquist Christensen
Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study. Neuropsychiatric disease and treatment 20 (2024)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Michael Cronquist Christensen, Roger S McIntyre, Michael Adair, Ioana Florea, Henrik Loft, Andrea Fagiolini
Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder. CNS spectrums (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) 38 (2) (2023)
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. Journal of psychopharmacology (Oxford, England) (2023)
Sergio De Filippis, Anna Pugliese, Michael Cronquist Christensen, Gianluca Rosso, Marco Di Nicola, Kenneth Simonsen, Hongye Ren
Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study. Neuropsychiatric disease and treatment 18 (2022)
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions. Annals of general psychiatry 21 (1) (2022)
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Emotional blunting in patients with depression. Part I: clinical characteristics. Annals of general psychiatry 21 (1) (2022)
Susana S Almeida, Michael Cronquist Christensen, Kenneth Simonsen, Michael Adair
Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study. Journal of psychopharmacology (Oxford, England) (2022)
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life. Annals of general psychiatry 21 (1) (2022)
Mircea Polosan, Marc Rabbani, Michael Cronquist Christensen, Kenneth Simonsen, Hongye Ren
Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study. Neuropsychiatric disease and treatment 18 (2022)
Michael Cronquist Christensen, Simon Schmidt, Iria Grande
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. Journal of psychopharmacology (Oxford, England) 36 (5) (2022)
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Emotional blunting in patients with depression. Part III: relationship with psychological trauma. Annals of general psychiatry 21 (1) (2022)
Roger S McIntyre, Henrik Loft, Michael Cronquist Christensen
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatric disease and treatment 17 (2021)
Michael Cronquist Christensen, Roger S McIntyre, Ioana Florea, Henrik Loft, Andrea Fagiolini
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. CNS spectrums (2021)
Michael Cronquist Christensen, Ioana Florea, Annika Lindsten, David S Baldwin
Efficacy of vortioxetine on the physical symptoms of major depressive disorder. Journal of psychopharmacology (Oxford, England) 32 (10) (2018)